Results 41 to 50 of about 50,777 (219)

Iron Catalyzed Aryl–Aryl Kumada Cross‐Coupling: A Mechanistic and Computational Investigation

Angewandte Chemie, EarlyView.
Despite intense interest, the mechanism of iron‐catalyzed aryl–aryl cross‐coupling remains poorly understood. Combining Mössbauer spectroscopy, kinetics analysis, and DFT computations these studies reveal a novel Fe(I)/Fe(II)/Fe(III) catalytic for aryl–aryl cross‐coupling mediated by an Fe(II) PCNHCP Pincer complex. These findings close a key knowledge
Jatin Panda, Magali Gimeno, Amrita Gogoi, Zeqing Chen, Subhash Garhwal, Laura Levy, Alexander Kaushansky, Natalia Fridman, Jos Briggs‐Pritchard, Renana Gershoni‐Poranne, Michael L. Neidig, Graham de Ruiter   +11 more
wiley   +2 more sources

Celecoxib Enhances Radiosensitivity via Induction of G2-M Phase Arrest and Apoptosis in Nasopharyngeal Carcinoma

Cellular Physiology and Biochemistry, 2014
Background: Previous work has proposed that celecoxib may be able to enhance the effects of radiotherapy. However, the underlying mechanism of this activity has not yet been determined.
Shui-xing Zhang, Qian-hui Qiu, Wen-bo Chen, Chang-hong Liang, Biao Huang   +4 more
doaj   +1 more source

Evaluation of Celecoxib-Lactose Incompatibility Reactions at Solid State using Physicochemical Methods [PDF]

Journal of Research in Applied and Basic Medical Sciences, 2021
Background & Aims:  Drug excipient incompatibility evaluation is an important part of pre-formulation studies. Drug-excipient interaction may affect drug stability, bioavailability, therapeutic effects, efficacy, and safety.
Ali Fattahzadeh, Azin Jahangiri, Naser Ranjkeshzadeh, Faranak Ghaderi   +3 more
doaj  

Selective Cyclooxygenase-2 Inhibitor Prevents Cisplatin-induced Tumorigenesis in A/J Mice [PDF]

, 2012
Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-
Katayama, Hideki, Kishino, Daizo, Kiura, Katsuyuki, Kuyama, Shouichi, Mimoto, Junko, Okada, Toshiaki, Sato, Ken, Takigawa, Nagio, Tanimoto, Mitsune, Ueoka, Hiroshi   +9 more
core   +1 more source

The Effect of Lower-Limb Exercise on Pain Management of the Patients Undergoing Posterior Lumbar Fusion Surgery: A Retrospective Case-Control Study

Pain Research and Management, 2021
Purpose. The purpose of this study is to investigate the clinical effect of lower-limb exercise, when combined with celecoxib, on pain management of patients undergoing posterior lumbar fusion surgeries. Methods.
Tong Wu, Yong Ye
doaj   +1 more source

Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain [PDF]

, 2009
Background - The efficacy and safety of the association of celecoxib [a selective cyclooxygenase-2 (COX-2) inhibitor] and pregabalin (commonly used to control neuropathic pain), compared with monotherapy of each, were evaluated for the treatment of ...
Carlo Luca Romanò, Delia Romanò, Cristina Bonora, Giuseppe Mineo, RA Deyo, LG Hart, TS Carey, LH Pengel, JW Frymoyer, M Korff Von, CJ Woolf, R Baron, R Freynhagen, R Freynhagen, AM Kaki, NB Finnerup, MH Moskowitz, G Cruccu, I Gilron, I Gilron, JA Haythornthwaite, N Torrance, H Lesser, RW Richter, A Meunier, SS Reuben, G Singh, Bennett MI The, C Pérez, PD Roelofs, BR Stacey, LM Arnold, PJ Mease, A Gatti, MI Bennett   +34 more
core   +1 more source

Formulation, Characterization, and in Vivo Evaluation of Celecoxib-PVP Solid Dispersion Nanoparticles Using Supercritical Antisolvent Process

Molecules, 2014
The aim of this study was to develop celecoxib-polyvinylpyrrolidone (PVP) solid dispersion nanoparticles with and without surfactant using the supercritical antisolvent (SAS) process.
Eun-Sol Ha, Gwang-Ho Choo, In-Hwan Baek, Min-Soo Kim   +3 more
doaj   +1 more source

Celecoxib concentration predicts decrease in prostaglandin E\u3csub\u3e2\u3c/sub\u3e concentrations in nipple aspirate fluid from high risk women [PDF]

, 2008
BACKGROUND: Epidemiologic studies suggest that long term low dose celecoxib use significantly lowers breast cancer risk. We previously demonstrated that 400 mg celecoxib taken twice daily for 2 weeks lowered circulating plasma and breast nipple aspirate ...
Chen, Yin-Chieh, Flynn, John T., Hewett, John E., Qin, Wenyi, Rottinghaus, George, Ruhlen, Rachel L., Sauter, Edward R.   +6 more
core   +1 more source

How and why systemic inflammation worsens quality of life in patients with advanced cancer [PDF]

, 2017
Introduction: The presence of an innate host systemic inflammatory response has been reported to be a negative prognostic factor in a wide group of solid tumour types in both the operable and advanced setting, both local and distant.
Dolan, Ross D., Horgan, Paul G., McMillan, Donald C., McSorley, Stephen T., Roxburgh, Campbell S.D.   +4 more
core   +1 more source

Mapping Nanoscale Protein‐Corona Kinetics of DoE‐Optimized Perfluorocarbon Encapsulated‐PLGA Nanoparticles by In Situ, Time‐Resolved Synchrotron SAXS

Advanced Healthcare Materials, EarlyView.
A two‐phase workflow (OFAT screening followed by central composite design) maps how processing variables tune PFCE‐PLGA nanoparticle size, dispersity, surface charge, loading, and 19F‐MRI signal. In situ, time‐resolved synchrotron SAXS tracks albumin‐corona growth on intact dispersions and reveals PFCE‐dependent adsorption pathways.
Joice Maria Joseph, Maria Rosa Gigliobianco, Cristina Minnelli, Paolo Moretti, Francesco Spinozzi, Giovanna Mobbili, Sara Pistolesi, Cristina Casadidio, Gabriella Teti, Roberta Censi, Stefano Antonio Gattone, Piera Di Martino   +11 more
wiley   +1 more source